Accelerate.EU

?? Key Updates on the IAEA Safety Standard SSR-6 Revision Nuclear Medicine Europe has published its position on the proposed revision to the IAEA Safety Standard SSR-6, which regulates the safe transport of radioactive material. This document provides insights into the implications of the changes, particularly regarding the transportation of medical radionuclides and radiopharmaceuticals used in nuclear medicine and Targeted Alpha Therapies (TATs). At Accelerate. EU, we are committed to supporting discussions that help advance access to innovative radiopharmaceutical treatments. #NuclearMedicine #Radiopharmaceuticals #Astatine211#PatientAccess #AccelerateEU

?? ????????????????-??????: ?? ???????? ?????????????? ???? ???????????? ?????????????????? – ???????????????? ???????? ????????.?Renata Mikolajczak ?? How can we secure a sustainable supply of Astatine-211 and ensure its clinical translation for cancer care? ?? In this exclusive video, Prof. Renata Miko?ajczak shares why she joined Accelerate.EU and how our multidisciplinary collaboration is tackling key challenges. Astatine-211 holds transformative potential in radiopharmaceuticals, but there’s still work to be done. Watch now to learn how Accelerate.EU is paving the way for innovation! #AccelerateEU #Radiopharmaceuticals #Astatine211 #CancerResearch #Innovation #TargetedTherapy Institut Jules Bordet , IBA RadioPharma Solutions Institut de Cancérologie de l'Ouest (ICO), Erasmus MC, Arronax, Forschungszentrum Jülich, Rigshospitalet, K?benhavns Universitet - University of Copenhagen, INSERM, SCK CEN, Campus da Universidade de Coimbra na Figueira da Foz, TetraKit Technologies, Oncidium foundation, LabLogic Group, Vicomtech, Université libre de Bruxelles, National Centre for Nuclear Research

Our latest #newsletter is here! ?? Radiotheranostics Today: Voices Shaping the Future of #CancerCare In this edition, we bring together diverse voices to discuss the challenges and opportunities in #radiotheranostics, from expanding access and ensuring quality standards to driving education and collaboration. ?? How can we shape the future of radiotheranostics together? Read the insights, join the conversation, and help amplify stories of hope and innovation. ?? Read now: https://lnkd.in/eqkcNhdx #RadiotheranosticsToday #WorldCancerDay #UnitedByUnique #Oncidiumfoundation #RadioligandTherapy #HealthcareInnovation Tadashi Watabe Cristiana Gameiro Leila Safavi Richard Zimmermann Andrea Luna Mass?Danny Mena Cortes?UroTeragLATAM ALASBIMN Accelerate.EU Thera4Care Elba Etchebehere Jean-Luc Vanderheyden Cal Huntzinger Celia Correa von Hahn, M.S. Taylor P. Taylor Kirk Jess G. Andrew Lake Wooten Rebecca Lo bue Gauthier Roelants de Stappers Shenlan Liu Efrain Perini Elisa Cannarozzo

?? ????????????????-??????: ?? ???????? ?????????????? ???? ???????????????????????????????????????? "It's extraordinary what's happening, and astatine is going to play a role." — Yves Jongen, ?????????????? ?????? ?????????? ???????????????? ?????????????? ???? ?????? Astatine-211 is emerging as a key player in the future of theranostics, but what does it take to bring this promising isotope to clinical use? In this exclusive video, Yves Jongen shares his insights on: ? The exciting trends shaping the theranostic market ? The technical challenges in developing astatine production infrastructure ? How logistics must evolve to ensure global access Watch now to explore the future of astatine-based therapies! ???? #AccelerateEU Institut Jules Bordet , IBA RadioPharma Solutions Institut de Cancérologie de l'Ouest (ICO), Erasmus MC, Arronax, Forschungszentrum Jülich, Rigshospitalet, K?benhavns Universitet - University of Copenhagen, INSERM, SCK CEN, Campus da Universidade de Coimbra na Figueira da Foz, TetraKit Technologies, Oncidium foundation, LabLogic Group, Vicomtech, Université libre de Bruxelles, National Centre for Nuclear Research

?????????????????? ????????: ?????????????????? ?????? ?????? ???? ?????????????? ???? ?????????????? ???? ????????????????-?????? ?????????????????? ?????????????? ???? ???????????? ?????? ?????? ?????? We are delighted to announce that IBA and Framatome signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale production of Astatine-211 (211At), an alpha-emitting radioisotope across Europe and the United States. Charles Kumps, President of IBA RadioPharma Solutions:?"It is?the start of what we believe will be a strong partnership with a shared goal: building a global, reliable industrial network for the timely production and commercialization of Astatine-211 compounds. By leveraging our combined expertise in cyclotron technology and in nuclear medicine, we are creating the critical infrastructure necessary to unlock the full potential of these groundbreaking therapies.” ?? Read the Press Release →?https://bit.ly/42HCejr #IBA #Astatine211 #TAT #radioisotope #Theranostic #Alpha

?? Don't Miss Out on this Exclusive Webinar on Targeted Alpha Therapy! Join renowned experts Univ.-Prof. Dr. Frederik Giesel, MD, MBA (University Hospital of Dusseldorf) and Prof. Dr. Hugo Levillain (University Hospital of Brussels) as they share cutting-edge insights into Targeted Alpha Therapy.

???????????????????????? ?????? ?????????????????? ?????? ???????????? ???????????????? ???????????? ???????????? (????????) Did you know that 1 in 6 breast cancer cases is classified as triple negative (TNBC)? This challenging subtype lacks effective therapeutic targets and leaves those affected with limited options and a dismal prognosis when metastatic. ????????????????????. ???? ???? ???????????????? ????????. Dr. Geraldine Gebhart, MD, PhD, Oncological Clinical Director at the Nuclear Medicine Department of the University hospital of Brussels (HUB) and clinical trial lead for Accelerate. EU, is pioneering an innovative approach: 211 Astatine-dual FAPi therapy. This groundbreaking treatment links a potent therapeutic isotope to a protein in the tumor microenvironment, leveraging molecular imaging and theranostics to advance care. Through the power of collaboration between nuclear medicine physicians, oncologists, and translational researchers, Accelerate. EU is delivering a new treatment strategy for TNBC, addressing a critical unmet need in oncology. Together, we are reshaping the future of precision medicine for those living with cancer. Innovative Health Initiative (IHI)European Commission #AccelerateEU #TNBC #BreastCancer #Theranostics #MolecularImaging #OncologyInnovation Institut Jules Bordet , IBA RadioPharma Solutions Institut de Cancérologie de l'Ouest (ICO), Erasmus MC, Arronax, Forschungszentrum Jülich, Rigshospitalet, K?benhavns Universitet - University of Copenhagen, INSERM, SCK CEN, Campus da Universidade de Coimbra na Figueira da Foz, TetraKit Technologies, Oncidium foundation, LabLogic Group, Vicomtech, Université libre de Bruxelles, National Centre for Nuclear Research

?? Discover the Accelerate.EU Project ?? We are pleased to share the official video of the Accelerate. EU Project, which highlights our mission to improve access to innovative cancer therapies across Europe. Watch the video to discover our vision and the impact we strive to achieve! Let us know your thoughts—we’d love to hear from you! Innovative Health Initiative (IHI) European Commission #AccelerateEU #astatine211 #CancerCare #Radiotheranostics #HealthcareInnovation Institut Jules Bordet , IBA RadioPharma Solutions Institut de Cancérologie de l'Ouest (ICO), Erasmus MC, Arronax, Forschungszentrum Jülich, Rigshospitalet, K?benhavns Universitet - University of Copenhagen, INSERM, SCK CEN, Campus da Universidade de Coimbra na Figueira da Foz, TetraKit Technologies, Oncidium foundation, LabLogic Group, Vicomtech, Université libre de Bruxelles, National Centre for Nuclear Research

?? Spotlight on Astatine-211 ?? We thought this publication on Astatine-211 might interest you, as it highlights an isotope drawing growing attention for its potential in advancing targeted cancer therapies. ?? This work reflects the significant progress and promise of isotopes in nuclear medicine. Congratulations to the authors on this important contribution to the field! ?? What are your views on the potential of Astatine-211? Let’s exchange ideas! ?? #AccelerateEU #Theranostics #NuclearMedicine #Isotopes #Innovation Maarten Vanermen,?Mathilde Ligeour,?Maria-Cristina Oliveira,?jean-francois GESTIN,?Filipe Elvas,?Laurent Navarro?&?Fran?ois Guérard?

Let's take a moment to celebrate Jér?me Harray remarkable dedication and leadership in making the Accelerate. EU project a reality! Jér?me, your commitment has been instrumental in bringing together a diverse group of voices, working toward a shared goal. Your ability to unite people with purpose and your exceptional leadership have truly set a strong foundation for impactful results. Thank you for the countless hours and unwavering vision you’ve invested to make this project possible. We’re grateful to have you leading this initiative, paving the way for improved access to innovative #cancer treatments across Europe. #Leadership #AccelerateEU #Innovation #Astatine211 Innovative Health Initiative (IHI) European Commission IBA RadioPharma Solutions Institut Jules Bordet